ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Faculty Opinions recommendation of Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.13355993.14726100
◽
2011
◽
Author(s):
Jan Vermorken
Keyword(s):
Squamous Cell Carcinoma
◽
Cell Carcinoma
◽
Head And Neck
◽
Phase Ii
◽
Squamous Cell
◽
Phase Ii Study
◽
Line Treatment
◽
First Line
◽
Metastatic Squamous Cell Carcinoma
◽
First Line Treatment
Download Full-text
Related Documents
Cited By
References
Faculty Opinions recommendation of Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.13355993.791652823
◽
2012
◽
Author(s):
Marco Merlano
Keyword(s):
Squamous Cell Carcinoma
◽
Cell Carcinoma
◽
Head And Neck
◽
Phase Ii
◽
Squamous Cell
◽
Phase Ii Study
◽
Line Treatment
◽
First Line
◽
Metastatic Squamous Cell Carcinoma
◽
First Line Treatment
Download Full-text
Faculty Opinions recommendation of Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.13355993.14726135
◽
2011
◽
Author(s):
Pol Specenier
Keyword(s):
Squamous Cell Carcinoma
◽
Cell Carcinoma
◽
Head And Neck
◽
Phase Ii
◽
Squamous Cell
◽
Phase Ii Study
◽
Line Treatment
◽
First Line
◽
Metastatic Squamous Cell Carcinoma
◽
First Line Treatment
Download Full-text
Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck
Annals of Oncology
◽
10.1093/annonc/mdr367
◽
2012
◽
Vol 23
(4)
◽
pp. 1016-1022
◽
Cited By ~ 102
Author(s):
R. Hitt
◽
A. Irigoyen
◽
H. Cortes-Funes
◽
J.J. Grau
◽
J.A. García-Sáenz
◽
...
Keyword(s):
Squamous Cell Carcinoma
◽
Cell Carcinoma
◽
Head And Neck
◽
Phase Ii
◽
Squamous Cell
◽
Phase Ii Study
◽
Line Treatment
◽
First Line
◽
Metastatic Squamous Cell Carcinoma
◽
First Line Treatment
Download Full-text
972TiP Phase II study of intratumoral MK-1454 plus pembrolizumab compared with pembrolizumab monotherapy as first-line treatment for metastatic or unresectable, recurrent head and neck squamous cell carcinoma
Annals of Oncology
◽
10.1016/j.annonc.2020.08.1087
◽
2020
◽
Vol 31
◽
pp. S683
Author(s):
K.J. Harrington
◽
W.N. William
◽
A. Khilnani
◽
A.P. Algazi
Keyword(s):
Squamous Cell Carcinoma
◽
Cell Carcinoma
◽
Head And Neck
◽
Phase Ii
◽
Squamous Cell
◽
Phase Ii Study
◽
Line Treatment
◽
First Line
◽
Recurrent Head
◽
First Line Treatment
Download Full-text
123MO Monalizumab, cetuximab and durvalumab in first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): A phase II trial
Annals of Oncology
◽
10.1016/j.annonc.2021.10.142
◽
2021
◽
Vol 32
◽
pp. S1432
Author(s):
D.A. Colevas
◽
K. Misiukiewicz
◽
A.T. Pearson
◽
J. Fayette
◽
J.R. Bauman
◽
...
Keyword(s):
Squamous Cell Carcinoma
◽
Cell Carcinoma
◽
Head And Neck
◽
Phase Ii
◽
Squamous Cell
◽
Phase Ii Trial
◽
Line Treatment
◽
First Line
◽
Metastatic Squamous Cell Carcinoma
◽
First Line Treatment
Download Full-text
90TiP FRAIL-IMMUNE: A multicenter, prospective, single arm phase II of the combination of durvalumab with carboplatin and paclitaxel as first-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck not eligible to standard chemotherapy (GORTEC 2018-03)
Annals of Oncology
◽
10.1093/annonc/mdz449.043
◽
2019
◽
Vol 30
◽
pp. xi32
Author(s):
J. Fayette
Keyword(s):
Squamous Cell Carcinoma
◽
Cell Carcinoma
◽
Head And Neck
◽
Phase Ii
◽
Squamous Cell
◽
Line Treatment
◽
First Line
◽
Standard Chemotherapy
◽
Metastatic Squamous Cell Carcinoma
◽
First Line Treatment
Download Full-text
Observational study of the cetuximab relative dose intensity (RDI) in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Data on the maintenance and every two weeks use (DIRECT study)
Annals of Oncology
◽
10.1093/annonc/mdw376.19
◽
2016
◽
Vol 27
◽
pp. vi334
◽
Cited By ~ 2
Author(s):
J. Guigay
◽
E. Chamorey
◽
P. Céruse
◽
F. Mornex
◽
M. Degardin
◽
...
Keyword(s):
Squamous Cell Carcinoma
◽
Observational Study
◽
Cell Carcinoma
◽
Head And Neck
◽
Squamous Cell
◽
Dose Intensity
◽
Line Treatment
◽
First Line
◽
Metastatic Squamous Cell Carcinoma
◽
First Line Treatment
Download Full-text
Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): First results of phase II trial GORTEC 2008-03.
Journal of Clinical Oncology
◽
10.1200/jco.2011.29.15_suppl.5567
◽
2011
◽
Vol 29
(15_suppl)
◽
pp. 5567-5567
◽
Cited By ~ 8
Author(s):
J. Guigay
◽
J. Fayette
◽
A. Dillies
◽
C. Sire
◽
J. N. Kerger
◽
...
Keyword(s):
Squamous Cell Carcinoma
◽
Cell Carcinoma
◽
Head And Neck
◽
Phase Ii
◽
Squamous Cell
◽
Phase Ii Trial
◽
Line Treatment
◽
First Line
◽
First Results
◽
First Line Treatment
Download Full-text
926TiP Phase II trial of enoblituzumab plus retifanlimab or tebotelimab in first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M SCCHN)
Annals of Oncology
◽
10.1016/j.annonc.2021.08.1336
◽
2021
◽
Vol 32
◽
pp. S814
Author(s):
G. Obara
◽
J. Sun
◽
D. Loo
◽
C. Bohac
Keyword(s):
Squamous Cell Carcinoma
◽
Cell Carcinoma
◽
Head And Neck
◽
Phase Ii
◽
Squamous Cell
◽
Phase Ii Trial
◽
Neck Squamous Cell Carcinoma
◽
Line Treatment
◽
First Line
◽
First Line Treatment
Download Full-text
Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02)
Annals of Oncology
◽
10.1093/annonc/mdy040
◽
2018
◽
Vol 29
(4)
◽
pp. 1004-1009
◽
Cited By ~ 13
Author(s):
M. Tahara
◽
N. Kiyota
◽
T. Yokota
◽
Y. Hasegawa
◽
K. Muro
◽
...
Keyword(s):
Squamous Cell Carcinoma
◽
Cell Carcinoma
◽
Head And Neck
◽
Phase Ii
◽
Combination Treatment
◽
Phase Ii Trial
◽
Line Treatment
◽
First Line
◽
Metastatic Squamous Cell Carcinoma
◽
First Line Treatment
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close